HC Wainwright Has Negative Outlook for PolyPid Q3 Earnings

PolyPid Ltd. (NASDAQ:PYPD) – Investment analysts at HC Wainwright dropped their Q3 2025 earnings per share (EPS) estimates for PolyPid in a research report issued to clients and investors on Wednesday, August 13th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of ($0.39) for the quarter, down from their prior estimate of ($0.36). HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for PolyPid’s FY2025 earnings at ($2.02) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($0.88) EPS, FY2028 earnings at ($0.20) EPS and FY2029 earnings at $1.46 EPS.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.25).

Several other research analysts have also commented on PYPD. Craig Hallum reissued a “buy” rating and issued a $13.00 price objective (down from $15.00) on shares of PolyPid in a research report on Thursday. JMP Securities cut their price objective on PolyPid from $16.00 to $14.00 and set a “market outperform” rating on the stock in a research report on Tuesday, June 17th. Roth Capital reissued a “buy” rating on shares of PolyPid in a research report on Thursday. Finally, Wall Street Zen lowered PolyPid from a “hold” rating to a “sell” rating in a research report on Saturday. One research analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, PolyPid presently has an average rating of “Moderate Buy” and a consensus price target of $12.40.

PolyPid Price Performance

NASDAQ:PYPD opened at $3.45 on Friday. The business’s 50-day moving average is $3.50 and its two-hundred day moving average is $3.06. PolyPid has a 12 month low of $2.30 and a 12 month high of $3.93. The firm has a market capitalization of $54.86 million, a PE ratio of -0.90 and a beta of 1.40.

Institutional Trading of PolyPid

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Lumbard & Kellner LLC purchased a new stake in shares of PolyPid during the second quarter worth about $135,000. AIGH Capital Management LLC increased its position in shares of PolyPid by 13.6% during the first quarter. AIGH Capital Management LLC now owns 940,381 shares of the company’s stock worth $2,548,000 after acquiring an additional 112,514 shares during the last quarter. Finally, J. Goldman & Co LP purchased a new stake in shares of PolyPid during the fourth quarter worth about $391,000. 26.47% of the stock is owned by hedge funds and other institutional investors.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.